From ATMP development to market entry in the Netherlands, drug developers face complex challenges. To complement the previously published ATMP Handbook, FAST organized a three-part webinar series on these challenges. In these webinars, we brought together speakers from various organizations (such as universities, companies, the CBG, the CCMO, and patient organizations) to discuss these issues.

The case studies can be seen back:

March 11, 2025 (4:00-5:00 p.m.):

Case: LentiCure, Pim Pijnappel & Dirk van Asseldonk

March 18, 2025 (4:00-5:00 pm): 

Case: iSTOP-CP: intranasal Stem cells to Treat Perinatal brain injury and combat Cerebral Palsy by Manon Benders and Cora Nijboer of UMCU

March 25, 2025 (4:00-5:00 pm): 

Case: Libmeldy by Andreas Schuil of Orchard Therapeutics

With this we hope to have provided valuable insights and answers to the main bottlenecks in the development of ATMPs. If you still have questions you can ask them on the FAST Forum.

While much knowledge has already been shared, there are ongoing challenges in ATMP development. FAST remains committed to joining forces, and we hope you’ll stay involved as we move forward. Keep an eye on our website for more information and sign up for our monthly updates.